We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.


Journal Scan / Research · October 03, 2022

Cost-Effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-Risk Clear Cell Renal Cell Carcinoma

The Journal of Urology


Additional Info

Disclosure statements are available on the authors' profiles:

The Journal of Urology
Cost Effectiveness of Adjuvant Pembrolizumab after Nephrectomy for High Risk Renal Cell Carcinoma: Insights for Patient Selection from a Markov Model
J Urol 2022 Sep 06;[EPub Ahead of Print], V Sharma, KM Wymer, DD Joyce, J Moriarty, A Khanna, BJ Borah, RH Thompson, BA Costello, BC Leibovich, SA Boorjian

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Renal Cell Carcinoma Center of Excellence

Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.

Further Reading